Fulgent Genetics Bets On H2 Rebound After Tough Q1

Fulgent Genetics ((FLGT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Fulgent Genetics’ latest earnings call painted a mixed picture for investors. Management acknowledged a difficult first quarter marked by revenue decline, margin pressure and operating losses, but emphasized strategic moves that they believe set up a stronger second half. Completed acquisitions, a deepening therapeutic pipeline and technology advances were positioned as foundations for renewed growth.

Strategic acquisitions reshape pathology footprint

Fulgent closed the Bako Diagnostics and StrataDx deals in the first quarter of 2026, adding $2.6 million of revenue in the period. The acquisitions more than doubled the pathology sales force, expand its anatomic pathology presence and are expected to contribute roughly $53 million of revenue in the second half of 2026.

Balance sheet remains strong despite heavy cash use

The company ended the quarter with $604.7 million in cash, equivalents, restricted cash and marketable securities even after funding acquisitions and buybacks. Management expects to finish 2026 with about $636 million of cash, assuming a delayed tax refund arrives and no new extraordinary outlays occur.

Therapeutic pipeline gains momentum and visibility

Lead candidate FID-007 completed Phase II enrollment with 46 patients and showed encouraging early safety and efficacy, earning a rapid oral slot at ASCO and a planned end-of-Phase-II FDA meeting in the second half. FID-022 has finished dose level 3 and continues dose escalation, with the maximum tolerated dose expected later in 2026.

Full-year revenue outlook reaffirmed

Despite a soft start, Fulgent reiterated its 2026 revenue target of $350 million, implying about 8.5% year-over-year growth. Segment goals call for about $168 million from Precision Diagnostics, $162 million from Anatomic Pathology and $20 million from Biopharma Services, with no single customer expected to exceed 10% of sales.

AI and product innovation underpin growth story

Management highlighted steady progress in its EasioPath platform, now nearly 100% visual across cases and enhanced by a new dermatopathology AI auto-rotation tool launched in the quarter. Fulgent also integrated the Illumina TruPath Genome into a whole genome test designed to deliver a single, comprehensive report across roughly 20,000 genes.

Regulatory tailwinds for pharmacogenomics testing

The company secured MolDX approval and pricing for its DPYD pharmacogenomic test in the quarter, a key reimbursement milestone. Shifting clinical guidelines from major oncology bodies and regulators are expanding the clinical and commercial opportunity for DPYD testing, potentially boosting future precision medicine revenues.

Aggressive buybacks shrink share count

Fulgent repurchased 2.6 million shares during the quarter and another 0.5 million since, driving a lower expected average diluted share count of about 29 million for 2026. The reduced share base improves non-GAAP EPS guidance by $0.14 per share, even as the company continues to post losses.

Revenue contracts as key customer volume falls

First-quarter revenue came in at $71.1 million, down 3.2% from a year earlier and 14.6% sequentially from the prior quarter. The decline was mainly tied to around $6 million of lower volume from its largest customer, underscoring the impact of concentration and the importance of diversifying the base.

Precision Diagnostics segment under pressure

Precision Diagnostics revenue fell to $40.2 million, an 8.8% year-over-year drop and a 16.5% sequential decline. Management cited weaker volumes from a major customer along with seasonal and operational issues, weighing on both top line and profitability in the core testing business.

Margins compressed but expected to recover

GAAP gross margin was just 30.2% and non-GAAP gross margin 32.3% in the quarter, well below the company’s longer-term targets. Fixed costs spread over a smaller revenue base, backlog timing and seasonal dynamics hurt profitability, though guidance calls for full-year non-GAAP margins near 39% and roughly 42% by year-end.

Operating losses widen and cash burn accelerates

Fulgent reported a GAAP net loss of $24.8 million in the quarter, slightly worse than the prior period, and an adjusted EBITDA loss of about $15.2 million versus a $4.5 million loss previously. On a non-GAAP basis excluding certain items, the company lost roughly $11 million, or $0.36 per share, as it invests in growth and absorbs near-term headwinds.

Biopharma Services show volatility

Biopharma Services revenue rose 43.2% from a year earlier to $5.8 million, confirming structural growth in that niche. However, the segment dropped 28.0% sequentially, highlighting the lumpy nature of large biopharma contracts and the earnings volatility that can accompany them.

Acquisitions and buybacks drive sizable cash outflows

Quarterly cash declined by $100.8 million compared with the prior period, mainly from $56.6 million paid for Bako and StrataDx and roughly $40.1 million spent on share repurchases. Management tied a $49 million reduction versus original cash guidance directly to year-to-date buybacks, signaling a deliberate capital return choice.

Backlog and seasonality weigh on revenue recognition

Results were also hurt by a claims processing backlog that delayed revenue recognition and pressured reported margins. Weather-related lab shutdowns and January deductible resets added to the drag, but management expects these factors to normalize over coming quarters as operations catch up.

Delayed tax refund adds timing risk to cash

A roughly $106 million federal income tax refund has yet to be received due to government and processing delays, clouding short-term cash timing. While the refund is embedded in year-end cash forecasts, the uncertainty around its arrival remains a watch point for investors monitoring liquidity.

Guidance signals stronger second half despite losses

Management’s guidance calls for full-year 2026 revenue of $350 million with quarterly sales above $90 million from the second quarter onward, helped by about $53 million from Bako and StrataDx in the back half. They project a non-GAAP gross margin around 39%, a non-GAAP operating margin near -20%, a full-year non-GAAP EPS loss of $1.59 and year-end cash of about $636 million, assuming planned spend and receipt of the tax refund.

Fulgent’s earnings call underscored a company in transition, absorbing near-term financial strain while betting heavily on acquisitions, innovation and its therapeutic pipeline. For investors, the story hinges on whether management can convert these strategic moves into the promised second-half acceleration, margin recovery and a more diversified, durable revenue base.